FDA & Regulation, Drugs & Devices Katie Coffee FDA & Regulation, Drugs & Devices Katie Coffee

FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer

The FDA has approved Genentech's oral drug giredestrant, sold as Wilserdly, with everolimus for ESR1-mutated advanced breast cancer. In the evERA trial, median progression-free survival was 10 months versus 5.5 months, but overall survival data remain immature and the label is limited to ESR1-mutated disease.

Read More